Renal Cell Carcinoma

Real-World Study of Nivolumab in RCC Reinforces CheckMate Data

September 16, 2020

Real-world trial results demonstrated nivolumab had comparable overall survival results with those observed in the phase 3 CheckMate 025 study as treatment of patients with advanced renal cell carcinoma who received 1 or more prior lines of therapy.

Nivolumab/Ipilimumab Established as New Standard in Frontline sRCC

September 08, 2020

The combination of nivolumab plus ipilimumab demonstrated long-term survival and response benefits as treatment of poor- to intermediate-risk patients with advanced renal cell carcinoma with sarcomatoid features compared with sunitinib, according to published results from the phase 3 CheckMate 214 clinical trial.

Frontline Ilixadencel Plus Sunitinib Demonstrates Further Survival Benefit in mRCC

August 19, 2020

Frontline ilixadencel in combination with sunitinib as utilized in newly diagnosed patients with metastatic renal cell carcinoma in the phase 2 MERECA clinical trial has updated survival data, which indicates continued survival benefit with the combination over sunitinib alone.

FDA Grants New Designations to MK-6482 in RCC and VHL Disease

July 29, 2020

The FDA has granted a Breakthrough Therapy designation to MK-6482, a novel HIF-2a inhibitor, as treatment of patients with von Hippel-Lindau disease-associated renal cell carcinoma who have non-metastatic tumors that measure less than 3 centimeters in size, unless immediate surgery is needed. The FDA has also granted an Orphan Drug designation to MK-6482 for the treatment of VHL disease alone.